Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Titel:
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Auteur:
Chen, G. Feng, J. Zhou, C. Wu, Y.-L. Liu, X.-Q. Wang, C. Zhang, S. Wang, J. Zhou, S. Ren, S. Lu, S. Zhang, L. Hu, C.-P. Hu, C. Luo, Y. Chen, L. Ye, M. Huang, J. Zhi, X. Zhang, Y. Xiu, Q. Ma, J. Zhang, L. You, C.